Skip to main content

Drug Interactions between Bonisara and Paser

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

cyanocobalamin aminosalicylic acid

Applies to: Bonisara (cyanocobalamin / folic acid / pyridoxine / strontium gluconate) and Paser (aminosalicylic acid)

MONITOR: Limited data suggest that aminosalicylic acid may decrease the gastrointestinal absorption of vitamin B12. Coadministration of aminosalicylic acid 5 g orally has been reported to reduce the absorption of vitamin B12 by 55%. Clinically significant erythrocyte abnormalities have been reported; however, the body (primarily the liver) usually has a copious supply of vitamin B12 that can sustain a person for several years in the absence of adequate intake.

MANAGEMENT: Due to the potential for reduced vitamin B12 absorption, the manufacturer recommends that maintenance vitamin B12 be considered in patients on aminosalicylic acid therapy for longer than one month. As for the treatment of B12 deficiency-related anemia, non-oral routes of administration (e.g., parenteral, intranasal, sublingual) are generally preferred, which would bypass the potential interaction.

References

  1. Halsted CH, McIntyre PA (1972) "Intestinal malabsorption caused by aminosalicylic acid therapy." Arch Intern Med, 130, p. 935-9
  2. Palva IP, Rytkonen U, Slatulkkila M, Palva M (1972) "Drug-induced malabsorption of vitamin B12." Scand J Haematol, 9, p. 5-7
  3. Heinivaara O (1964) "Malabsorption of vitamin B112 during treatment with para-aminosalicylic acid: a preliminary report." Acta Med Scand, 175, p. 469-71
  4. Levine RA, (1968) "Steatorrhea induced by para-aminosalicylic acid." Ann Intern Med, 68, p. 1265
  5. "Product Information. Paser D/R (aminosalicylic acid)." Jacobus Pharmaceutical Company
View all 5 references

Switch to consumer interaction data

Drug and food interactions

Moderate

folic acid food

Applies to: Bonisara (cyanocobalamin / folic acid / pyridoxine / strontium gluconate)

MONITOR: Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics. Excessive alcohol consumption may lead to folate deficiency.

MANAGEMENT: Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
  4. Cerner Multum, Inc (2015) "ANVISA Bulário Eletrônico."
  5. (2017) "Product Information. Folic Acid (folic acid)." Method Pharmaceuticals, LLC
View all 5 references

Switch to consumer interaction data

Moderate

strontium gluconate food

Applies to: Bonisara (cyanocobalamin / folic acid / pyridoxine / strontium gluconate)

ADJUST DOSING INTERVAL: Concomitant administration of strontium with food or milk products may decrease its bioavailability by 60% to 70%.

MANAGEMENT: Strontium salts should be taken at least two hours before or two hours after food or milk products, and preferably at bedtime.

References

  1. (2007) "Product Information. Bonisara (cyanocobalamin/folic acid/pyridoxine/strontiu)." Zylera Pharamaceuticals

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer